Sera Prognostics appoints Lee Anderson as Chief Commercial Officer; 30-year diagnostics veteran to lead PreTRM rollout

SERA PROGNOSTICS, INC.

Lee Anderson appointed CCO effective May 8, 2025; reports to CEO Zhenya Lindgardt.
Anderson previously led US Oncology Sales at Genomic Health (acquired by Exact Sciences) and was CCO at Biofidelity.
He will drive commercial adoption of the PreTRM test following positive PRIME study results.
Company is in commercial phase; Anderson brings over 30 years of healthcare sales and marketing leadership.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.